Summary: Researchers at the University of Bath have refined a peptide molecule that shows promise for preventing Parkinson’s disease.
Source: University of Bath
Scientists at the University of Bath have improved a peptide molecule that could form the basis of a future drug to prevent or slow the progression of Parkinson’s disease.
Professor Jody Mason from the Department of Biology and Biochemistry, who led the study, emphasized that while further work is required, the optimized molecule represents a promising starting point for a disease‑modifying treatment. “Current medicines only address symptoms,” she said. “Our goal is to develop a therapy that protects brain cells before clinical symptoms arise and preserves patient health.”
Parkinson’s disease is driven in part by the misfolding and aggregation of a brain protein called alpha‑synuclein (αS). Normally abundant in human brains, alpha‑synuclein can adopt abnormal shapes and clump together into Lewy bodies—large aggregates that are toxic to dopamine‑producing neurons. The loss of these neurons reduces dopamine signaling, leading to the motor symptoms such as tremor and slowed movement that define the disease.
Prior work at Bath screened a vast intracellular library of 209,952 peptides to find sequences able to block the initial misfolding and aggregation of αS. From that screen, a ten‑residue peptide named 4554W emerged as the most effective candidate, preventing αS from aggregating into toxic species in test‑tube and cell culture experiments.
Building on those results, the research team refined 4554W to enhance its inhibitory activity. The redesigned peptide, called 4654W(N6A), incorporates two changes to the original amino‑acid sequence and demonstrates significantly greater ability to reduce αS misfolding, aggregation and resulting cellular toxicity in laboratory studies. Despite these encouraging findings, the researchers caution that translating a peptide into a safe, effective drug will require substantial additional development and testing over many years.
Dr. Richard Meade, lead author of the study, explained why peptides are a promising therapeutic approach for this target: “Small‑molecule drugs have struggled to block alpha‑synuclein aggregation because they’re often too small to disrupt the extensive protein–protein interactions involved. Peptides strike a balance: large enough to interfere with aggregation, yet potentially suitable for drug development.”
Meade added that 4654W(N6A) is particularly exciting because it not only reduces aggregation and improves cell survival in culture but also helps pinpoint the specific region of alpha‑synuclein to target therapeutically. “This work advances both potential treatments and our fundamental understanding of why alpha‑synuclein misfolds,” he said.
Professor Mason noted the next steps will focus on making the peptide more drug‑like and capable of reaching neurons in the brain. “We need to modify the molecule so it crosses biological membranes and penetrates brain cells. That may involve moving beyond natural amino acids toward laboratory‑synthesized building blocks to boost stability, delivery and efficacy,” she said.
Beyond Parkinson’s disease, the findings may have wider relevance for other conditions where protein misfolding plays a role, including Alzheimer’s disease and Type 2 diabetes. Identifying molecules that block pathological protein aggregation without disrupting normal protein function is a key therapeutic aim across multiple disorders.
Dr. Rosa Sancho, head of research at Alzheimer’s Research UK, welcomed the work, noting that strategies to prevent alpha‑synuclein from becoming toxic could open new drug development pathways for Parkinson’s and related disorders. She acknowledged that the molecule will need further refinement and extensive testing before any clinical use, but called the discovery a promising step toward a future disease‑modifying treatment.
About this Parkinson’s disease research news
Author: Press Office
Source: University of Bath
Contact: Press Office – University of Bath
Image: The image is in the public domain
Original Research: Closed access.
“A Downsized and Optimised Intracellular Library‑Derived Peptide Prevents Alpha‑Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding” by Richard M. Meade et al. Journal of Molecular Biology
Abstract
A Downsized and Optimised Intracellular Library‑Derived Peptide Prevents Alpha‑Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding
Misfolding and aggregation of alpha‑synuclein (αS) within dopaminergic neurons are central to the development and progression of synucleinopathies, including Parkinson’s disease. Earlier work screened a 209,952‑member intracellular peptide library and used the preNAC region (residues 45–54) as a design guide, yielding the ten‑residue inhibitor 4554W. This peptide was shown to block αS aggregation at the stage of primary nucleation induced by lipid surfaces, thereby preventing formation of downstream cytotoxic species.
In the present study, the authors combined systematic truncation and a full alanine‑scan to map the residues responsible for inhibitory activity and to identify positions that tolerate modification. They discovered that an N‑terminal truncation together with an N6A substitution produced a peptide—4654W(N6A)—with markedly improved efficacy.
Importantly, experiments indicate the optimized peptide does not disrupt αS binding to lipid vesicles, a desirable property because preserving native αS association with small synaptic neurotransmitter vesicles helps maintain normal dopaminergic vesicle fusion and recycling. The work therefore advances the goal of producing a potent peptide antagonist of αS pathogenicity that leaves native protein function intact.